In this episode, Srihari S Naidu shares his career tips for young, ambitious cardiologists and what he has learnt about mentorship from his numerous leadership positions. Hari elaborates on the different types of mentorship, the importance of developing non-academic skills, why you should focus on your strengths rather than weaknesses, and the fickle art of managing one’s public/private personas as a young cardiologist in an era of social media.
Having recently applied for the programme himself, Ankur also speaks with Hari about the history, purpose and future of the Society for Cardiovascular Angiography and Interventions (SCAI) Emerging Leader Mentorship (ELM) Fellowship Programme. Submit your question to: podcast@radciffe-group.com. Guest @SrihariNaiduMD.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Ahead of TCT 2019, Ankur and Hari also talk about which trials presented in San Francisco they are most excited about! Submit your question to Ankur via: podcast@radciffe-group.com. Guest @SrihariNaiduMD.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Ankur is back with his second #AudioArticle! This week he spoke with Santiago Garcia from the Minneapolis Heart Institute about Santiago’s US Cardiology Review 13.1 article on the role of high-sensitivity cardiac troponin (hscTn) assays and their ability to rapidly rule in or rule out acute coronary syndrome (ACS) with improved sensitivity.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Ankur is back with his second #AudioArticle! This week he spoke with Santiago Garcia from the Minneapolis Heart Institute about Santiago’s US Cardiology Review 13.1 article on the role of high-sensitivity cardiac troponin (hscTn) assays and their ability to rapidly rule in or rule out acute coronary syndrome (ACS) with improved sensitivity.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.